Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Bear Stearns Cuts Schering-Plough Estimates


Investment bank Bear Stearns cut its estimates on drug maker Schering-Plough (SGP) after the company said that its earnings per share for the first quarter would be as much as 15% lower than previously expected due to manufacturing problems.

Analyst Joseph Riccardo cut his first quarter 2001 EPS to $1.65 from $1.90 and lowered his 2002 EPS to $1.90, down from $2.17. He notes, however, that there is very little information to base estimates on at this time. Riccardo mentioned Claritin may be negatively impacted by deficiencies at its New Jersey and Puerto Rico facilities. He said the company should be able to post EPS of $2.00 in the 2002 to 2003 time frame.

He noted investors have historically done well by buying drug stocks on negative news and takeover speculation should strengthen the company's share price. His price target on the stock is $55 to $60.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus